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ABSTRACT
Objective: To estimate the average postponement of
death in statin trials.
Setting: A systematic literature review of all statin
trials that presented all-cause survival curves for
treated and untreated.
Intervention: Statin treatment compared to placebo.
Primary outcome measures: The average
postponement of death as represented by the area
between the survival curves.
Results: 6 studies for primary prevention and 5 for
secondary prevention with a follow-up between 2.0 and
6.1 years were identified. Death was postponed
between −5 and 19 days in primary prevention trials
and between −10 and 27 days in secondary prevention
trials. The median postponement of death for primary
and secondary prevention trials were 3.2 and 4.1 days,
respectively.
Conclusions: Statin treatment results in a surprisingly
small average gain in overall survival within the trials’
running time. For patients whose life expectancy is
limited or who have adverse effects of treatment,
withholding statin therapy should be considered.
INTRODUCTION
HMG-CoA reductase inhibitors—or
‘statins’—are important drugs for the preven-
tion of atherosclerotic conditions such as
stroke, myocardial infarction or limb ischae-
mia.1 Current guidelines indicate that statins
should be prescribed to all patients manifest-
ing ischaemia and to other patients at high
risk,1 2 and that statins are among the most
widely prescribed drugs overall.3
The magnitude of their preventive effect is
controversial; also controversial is how such
effects should be conveyed to the patients.4
The number needed to treat (NNT) has been
widely endorsed as a useful effect measure for
clinical practice. Its popularity is based on the
belief that the NNT conveys drug effects to
physicians and their patients in a single, easily
understood measure.5 However, it has been
shown that patients6–9—and to some extent
prescribers10—are not responsive to the NNT
value, that is, their choices of whether or not
to take or to prescribe the drug are largely
unaffected by the NNT values given. Also,
NNT may be criticised for not conveying a
plausible model for how the beneﬁt of statins
is distributed.10 The thinking behind NNT sug-
gests a lottery-like model, where, for example,
1 patient in 40 receives full beneﬁt from the
drug, while in the remaining 39 patients, it has
no effect. It is more plausible that statins will
delay atherosclerotic progression in all those
treated, to an extent where 1 in 40 patients will
have his or her end point postponed until
after the outcome is measured. The remaining
39 patients will also have their end points post-
poned, but none to an extent where they cross
this timeline. As an alternative to the NNT, it
has been suggested that the drug beneﬁt may
be conveyed by an estimate of the average post-
ponement in the occurrence of the end point
for all treated.4 It has been shown that patients
are more responsive to values of postpone-
ment than to values of NNT.7 Technically, the
average postponement can be calculated as
the area between the survival curves for the
treated and the untreated.11
To the best of our knowledge, statins have
not been systematically assessed in an
outcome postponement model. We identiﬁed
statin trial reports that provided all-cause sur-
vival curves for treated and untreated, and
calculated the average postponement of
death as represented by the area between the
survival curves.
Strengths and limitations of this study
▪ This is the first study ever to systematically
evaluate statin trials using average postponement
of death as the primary outcome.
▪ We have only estimated the survival gain
achieved within the trials’ running time, whereas
in real life, treatment is often continued much
longer.
▪ We have only focused on all-cause mortality.
Other outcomes may also be relevant, for
example, non-fatal cardiovascular end points.
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MATERIALS
Search and inclusion of trials
We based our study on a meta-analysis on the effect of
statins on cardiovascular morbidity or survival, published
by Baigent et al.12 The Baigent paper had retrieved all
relevant papers published until the end of 2009. We sup-
plemented the Baigent search and included the period
2010–2011. Our supplementary literature search yielded
one further paper.13
The included trials in our analysis were deﬁned by
being randomised, having at least 1000 patients
included, comparing a statin with no treatment or
placebo, having at least 2 years of follow-up, having all-
cause mortality as a pre-speciﬁed primary or secondary
end point and by providing a Kaplan-Meier plot of
all-cause mortality in treated versus untreated in the
publication. The 11 included papers are listed in table 1.
We have listed the excluded papers in online supplemen-
tary appendix A, also giving the reason for exclusion.
ANALYSIS
An example of the technical aspects of area calculations
is shown in online supplementary appendix B. In brief,
we magniﬁed the Kaplan-Meier graphs from the publica-
tions by 300% and imported them into Paint (Microsoft
Windows V.7). Ten of 11 publications were available in
electronically processed format, the last14 was available
in a scanned copy. A vertical line was drawn at the cut
point according to the original publication. A reference
area was drawn in the lower left corner of the graph,
using the tick marks of the x and y axes in the original
graph. The number of pixels in the reference area was
calculated by multiplying the measured number of
pixels at the length and height of the drawn box. The
graph was then imported into Adobe Photoshop (Adobe
Systems, San Jose, California, USA), and the number of
pixels between the survival curves was counted using the
polygonal lasso tool. We counted the area in segments,
with better survival in the untreated group as negative,
and we used the cut point as the right border of the
area between survival curves. If no cut point was given,
we used the latest time both survival curves were drawn
in the original Kaplan-Meier plot. If more than one cut
point was used in the original publication, we chose the
latest. All area calculations were carried out in triplicate
by three independent observers, to assess the variance of
the area calculations.
We also calculated all areas in a less technical manner,
that is, by drawing one or more triangles by hand on
magniﬁed paper prints of the survival curve for each
study and then calculating the areas of these triangles by
standard arithmetic. This is referred to as the quick
method.
We categorised the studies as being in primary or sec-
ondary prevention, depending on whether the study
included participants with manifest cardiovascular
disease prior to randomisation. We calculated summary
estimates of ORs for all-cause mortality separately for
included as well as excluded studies using a standard
meta-analysis technique.15
RESULTS
Of the 26 publications provided in the original
meta-analysis and the one retrieved by literature search,
11 could be included in our analysis. The most common
reason for exclusion was lack of a KM survival plot for
treated and untreated (9 studies). Among the included
studies, six were on primary prevention and ﬁve were on
secondary prevention.
The calculated end point postponement values are
given in table 1, together with the effect measures pro-
vided in the original publications. Death was postponed
between −5 and 19 days in primary prevention trials and
between −10 and 27 days in secondary prevention trials.
The median postponement of death for primary and
secondary prevention trials were 3.2 and 4.1 days,
respectively.
The quick method provided estimates that deviated
from the pixel count method by <1 day in 7 of 11 trials
(64%). The maximum difference between the two
methods was 4.8 days, for the 4S trial (table 1).
The summary OR for all-cause mortality from the
included trials was 0.89 (CI 0.84 to 0.93), compared to
0.91 (CI 0.86 to 0.96) for the excluded trials.
DISCUSSION
To the best of our knowledge, statin trials have not previ-
ously been subjected to a systematic assessment of sur-
vival gain by this technique. The survival gains we found
are surprisingly small. The highest value was 27 days,
found in the 4S study, achieved by 5.8 years of simvasta-
tin therapy in participants with a history of unstable
angina or myocardial infarction. Experience from
studies of preferences, when presented with similar scen-
arios, shows that as many as 70% of lay persons would
not accept such a treatment.16
There are a number of caveats that need to be consid-
ered. First, this analysis only estimates the survival gain
achieved within the trials’ running time. After termin-
ation of the trials, the treated would continue to accrue
survival gain as long as there was a difference in cumula-
tive mortality between the treatment arms. There are a
few studies with long-term follow-up after cardiovascular
intervention trials showing that this survival might be
substantial,17 but there are also studies showing that
mortality becomes similar in the two groups after the
trial’s termination.18 Some modelling studies have sug-
gested a large survival beneﬁt with long-term treatment
beyond the trial’s running time,19 but obviously this con-
clusion relies heavily on model assumptions. Second,
our analysis is based on the assumption that survival
gain is uniform among the treated. The true distribution
is unknown, and some authors have suggested that a
hybrid model of classical NNT thinking along with a
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Table 1 Estimated postponement of death in 11 trials comparing statin therapy with no treatment or placebo
Study ID, reference,
publication year
Number
included
Intervention/
comparator Prevention
Cut
point,
years
Dead:
statin/
control, % RR (95% CI) NNT
Postponement,
days (SD)
Postponement,
quick method,
days
ALLHAT-LLT22 2002 10 355 Pravastatin (40 mg) vs
usual care
Primary 6 14.9/15.3 0.99 (0.89 to 1.11) 250 −4.96 (0.06) −5.48
ASCOT-LLA23 2003 19 342 Atorvastatin (10 mg) vs
placebo
Primary 3.5 3.6/4.1 0.87 (0.71 to 1.06) 200 1.99 (0.04) 1.94
CARDS24 2004 2838 Atorvastatin (10 mg) vs
placebo
Primary 4.8 4.3/5.8 0.73 (0.52 to 1.01) 66.7 18.66 (0.04) 17.21
JUPITER25 2008 17 802 Rosuvastatin (20 mg) vs
placebo
Primary 4 2.22/2.77 0.80 (0.67 to 0.97) 31 7.26 (0.01) 7.25
MEGA26 2006 7832 Pravastatin (5–20 mg) vs
no treatment
Primary 5 1.11/1.66 0.68 (0.46 to 1.00) 182 4.42 (0.01) 4.47
WOSCOPS27 1995 6595 Pravastatin (40 mg) vs
placebo
Primary 5 3.2/4.1 0.78 (0.60 to 1.00) 111 9.33 (0.10) 8.29
4S28 1994 4444 Simvastatin (10–40 mg)
vs placebo
Secondary 5.8 8.7/12.3 0.7 (0.58 to 0.85) 27.8 27.18 (0.26) 31.96
GISSI-HF29 2008 4631 Rosuvastatin (10 mg) vs
placebo
Secondary 4.4 28.8/28.1 1.00 (0.90 to 1.12) −143 −9.51 (0.01) −10.44
GISSI-P14 2000 4271 Pravastatin (20 mg) vs no
treatment
Secondary 2.0 3.37/4.13 0.84 (0.61 to 1.14) 132 1.76 (0.07) 2.53
LIPID30 1998 9014 Pravastatin (40 mg) vs
placebo
Secondary 6.1 11.0/14.1 0.78 (0.69 to 0.87) 32.3 22.05 (0.21) 26.59
CORONA13 2007 5011 Rosuvastatin (10 mg) vs
placebo
Secondary 2.7 29.0/30.4 0.95 (0.86 to 1.05) 71 4.09 (0.04) 4.16
NNT, number needed to treat; RR, relative risk.
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postponement model could be used.8 This model would
convey something similar to ‘simvastatin resulted in an
average of 8 months’ postponement of heart attacks for
one of four patients’.8 Unfortunately, this model is
highly speculative. There are no empirical clues as to
what proportion of patients will have their outcome post-
poned. In addition, there is very limited experience
about the extent to which the hybrid model is under-
stood by patients and how it affects their choices. Third,
we have only focused on all-cause mortality in our ana-
lysis. Other outcomes may also be relevant. For example,
we calculated the area between Kaplan-Meier curves for
‘any cardiovascular end point’ in the 4S trial, and found
an average postponement of 109 days. A systematic post-
ponement analysis of end points other than all-cause
mortality might thus be warranted. Fourth, we could
only include 11 of 27 trials, and we need to consider the
possibility that the low postponement values may be
explained by selection bias. However, the summary esti-
mates of ORs for all-cause mortality observed in the
included or excluded trials do not indicate a better
intervention effect in excluded trials. If anything, the
included studies seem to have a marginally more favour-
able result.
There are a number of technical caveats as well. The
method used to estimate the area between the
Kaplan-Meier curves may seem too technical for routine
use. However, it was reassuring to see that the quick-
method produced nearly identical results. None of the
quick-method estimates deviated more than 5 days from
the pixel-count estimates, and most deviations were
below 1 day. Also, on a technical note, the SEs provided
in this paper refer to the area calculations alone and not
to the overall effect of the intervention. For example, a
single underpowered study is likely to have a HR in
which CI crosses the null value. That the intervention is
harmful cannot be ruled out from this study alone. Yet,
the survival curves may show good separation, and the
area between curves might be calculated with little
uncertainty. Unfortunately, a statistical model has not yet
been developed that incorporates the uncertainty of the
net beneﬁt of the drug, such as the CI of the HR, into a
postponement model. Consequently, there are currently
no methods to perform meta-analyses of outcome
postponement.
What are the clinical implications of our ﬁndings? We
believe that statins should be prescribed according to
the prevailing guidelines. Statins are usually inexpensive
and safe, at least in a clinical trial setting,20 and the
beneﬁt in terms of mortality or non-fatal cardiovascular
outcomes cannot reasonably be challenged. However, if
the patient has intolerance or unpleasant side effects
from statins, for example, muscular problems, physicians
should not be too insistent on the patient continuing
them. Also, for patients whose life expectancy is short,
the beneﬁt of statin therapy in terms of survival gain
may be quite limited.21 The physician might consider
using postponement measures to communicate the
beneﬁt to the patients, instead of the NNT or relative
risk reductions, which are so prone to misunderstand-
ing. Admittedly, calculating postponement values may
seem too technical for routine use by a typical pre-
scriber. However, it is our hope that the postponement
approach could be adopted by researchers or authors of
guidelines as a supplementary mean of communicating
drug beneﬁt.
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